New Equol Complement For Relieving Menopausal Symptoms: Rand : Menopause
Ishiwata, Naoko PhD1; Melby, Melissa Okay. PhD2; Mizuno, Shoichi PhD2; Watanabe, Shaw MD, DSc2
From the 1Department of Life Environments Administration, Atomi College, Nakano, Niza-shi, Saitama, Japan; and 2National Institute of Health and Nutrition, Toyama, Shinjyuku-ku, Tokyo, Japan.
Received March 30, 2008; revised and accepted Might 27, 2008.
Monetary support: Otsuka Pharmaceutical Co Ltd, Japan, supplied the supplement and monetary support.
Monetary disclosure: None reported.
Address correspondence to: Naoko Ishiwata, PhD, Department of Life Environments Administration, Atomi University, 1-9-6 Nakano, Niza-shi, Saitama 352-8501, Japan. E-mail: [e mail protected]
Purchase
Abstract
Objectives:
Equol, a metabolite of the isoflavone daidzein, is hypothesized to play a serious position within the health advantages of soy. We examined the effect of a brand エクオール（及びエクオール サプリ） new S-equol complement on menopausal signs and mood states.
Design:
We conducted a randomized, double-blind, placebo-controlled trial with our new equol supplement for 12 weeks with 134 Japanese women (aged 40-59 years). They have been randomly assigned to three teams: placebo (n = 44), 10 mg of equol per day (EQ-1; n = 44), and 10 mg of equol thrice per day (EQ-3; n = 46). Habitual isoflavone intake was restricted to 20 mg/d. Participants completed menopausal symptom and Profile of Temper States questionnaires at baseline and postintervention. Physical examination and blood and 24-hour urine collection have been carried out at baseline and postintervention.
Outcomes:
At baseline, total menopausal symptom rating assorted by menopausal and equol producer standing (34.3% producers). A total of 127 participants (94.8%) completed the trial. No adversarial results have been reported, aside from a systemic rash in one EQ-three woman. The anxiety scores of equol producers have been decrease than those of nonproducers (P < 0.05). Significant differences between premenopausal and perimenopausal/postmenopausal symptom scores were observed for anxiety, somatic, and total scores. After the EQ-3 intervention, perimenopausal/postmenopausal equol nonproducers showed significant decreases from baseline in all menopausal symptom scores except depression (P < 0.01). Compared with placebo, the EQ-3 group showed significant decreases in depression scores (P < 0.05), as well as significant decreases in Tension-Anxiety (P < 0.05), Depression-Dejection (P < 0.05) and Fatigue (P < 0.01) and increases in Vigor (P < 0.05) of the Profile of Mood States.
